The largest database of trusted experimental protocols
> Disorders > Sign or Symptom > Neurobehavioral Manifestations

Neurobehavioral Manifestations

Neurobebehavioral Manifestations: Explore the intricate interplay between the nervous system and behavior.
This term encompasses a wide range of neurological and psychological expressions, from cognitive and emotional processing to sensory-motor integration.
Uncover the latest insights into this dynamic field and optimize your research with PubCompare.ai's innovative solutions.

Most cited protocols related to «Neurobehavioral Manifestations»

All ADNI CN and MCI participants were diagnostically reclassified using Jak/Bondi actuarial neuropsychological test methods [24 (link), 25 (link)] applied to their baseline data. Six neuropsychological measures from ADNI were chosen because of their routine use in assessing early cognitive manifestations of AD and administration across all three ADNI grant periods (ADNI-1, -GO, and -2). The six measures were Category Fluency and Boston Naming Test scores for the language domain, Trail-Making Test Parts A and B scores for the graphomotor speed/executive function domain, and Rey AVLT delayed recall and delayed recognition scores for the episodic memory domain. None of these cognitive measures were used in making the initial ADNI diagnostic classification. Each measure was converted to an age-corrected standard score using published normative data: Mayo Older Americans Normative Study data (n = 530; [36 ]) for the Rey AVLT and National Alzheimer’s Coordinating Center normative data (n = 3,286; [37 (link), 38 (link)]) for the remaining neuropsychological measures. Participants were considered to have MCI if any one of the following three criteria were met: 1) they had an impaired score, defined as >1 SD below the age-corrected normative mean, on both measures within at least one cognitive domain (i.e., memory, language, or speed/executive function); 2) they had one impaired score, defined as >1 SD below the age-corrected normative mean, in each of the three cognitive domains sampled; or 3) they had a score on the FAQ =9 indicating dependence in three or more daily activities. This latter criterion approximated Jak, Bondi et al.’s [25 (link)] incorporation of instrumental ADL assessment to diagnosis and reflects significant study partner-rated difficulties in everyday function. If none of these criteria were met, the participant was diagnosed as CN.
Publication 2014
Cognition Executive Function Memory Memory, Episodic Mental Recall Neurobehavioral Manifestations Neuropsychological Tests

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2016
Anger Anxiety Arousal Cardiovascular System Cognition Discrimination, Psychology Fatigue Fear Feelings Felis catus Malignant Neoplasms Medically Unexplained Symptoms Nervousness Neurobehavioral Manifestations Reading Frames Sleep
First, existing screening and diagnostic instruments for ICDs and other compulsive behaviors that have been used in PD and the general population were reviewed(1 ;6 (link);19 (link);21 (link)–23 (link)). Second, input was solicited from outside experts in the area of ICDs in PD (MNP, JM, and VV) and from an expert in questionnaire development (JAS). Third, a preliminary ICD section of the QUIP was structured to be consistent with diagnostic criteria or defining clinical characteristics as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)(1 ). This consisted of an introductory question and four additional questions that addressed cognitive symptoms, affective symptoms, lack of ability to reduce or stop the behaviors, and activities that enable continuation of the behaviors. The compulsive medication use section was modeled on both Giovannoni’s proposed criteria for hedonistic homeostatic dysregulation and DSM-IV substance dependence criteria. While minor wording changes were made in subsequent drafts, the structure of these sections remained consistent throughout the instrument development process. The other compulsive behaviors section was designed with conciseness in mind (an introductory question for each of the three behaviors plus two common additional questions). Guiding principles in the design of the QUIP included making it self-administered, brief yet comprehensive, and consistent in wording across different ICDs and other compulsive behaviors.
Next, the preliminary QUIP was administered to a sample of healthy controls (10 research staff members who work with neurodegenerative disease and psychiatric populations), and modifications were made based on the feedback received. Finally, the QUIP was administered to five PD patients and their informed others, and additional modifications were made based on the feedback received from them.
The final version that was validated queried about behaviors that occurred at any time since the onset of PD (either inactive or active) that lasted at least four weeks. We chose the time frame of “anytime during PD” due to the observation that a substantial number of PD patients who have experienced an ICD during PD are currently asymptomatic due to clinical management, but may be at elevated risk of developing an ICD in the future. Another version of the QUIP that queries only about active behaviors is also available; it is identical to the validated version except for the time frame queried. The final version of the QUIP is divided into three sections: (1) five questions (including an introductory question that defines and gives examples of problem behaviors) for the four ICDs reported in PD; (2) three distinct introductory questions and two common additional questions for hobbyism, punding, and walkabout; and (3) five questions (including an introductory question) for compulsive medication use. The Flesch-Kincaid Readability Test assessed the QUIP to require a 12th grade reading level.
Publication 2009
Affective Symptoms Compulsive Behavior Diagnosis Homeostasis Implantable Defibrillator Neurobehavioral Manifestations Neurodegenerative Disorders Patients Pharmaceutical Preparations Population Group Problem Behavior Reading Frames Substance Dependence
Cerebral SVD is characterized on neuroimaging by either WML or lacunar infarcts. Symptoms of SVD include acute symptoms, such as transient ischemic attack (TIA) or lacunar syndromes, but also subacute manifestations such as cognitive and motor (gait) disturbances [5 (link)]. As the onset of cerebral SVD is often insidious, clinically heterogeneous, and typically with mild symptoms, it has been suggested that the selection of subjects with cerebral SVD in clinical studies should be based on the more consistent brain imaging features [20 (link)].
Accordingly, in 2006, consecutive individuals referred to the Department of Neurology between October 2002 and November 2006, were selected for possible participation. Inclusion criteria were: (a) age between 50 and 85 years; (b) cerebral SVD on neuroimaging (WML and/or lacunar infarcts). Subsequently, the above mentioned acute and subacute clinical symptoms of SVD were assessed by standardized structured assessments (a questionnaire for TIA and stroke [21 (link)]; for cognition the Cognitive Failures Questionnaire [22 (link)]; for gait the Falls Questionnaire [23 (link)] and the Freezing of Gait Questionnaire [24 (link)]) Subjects who were eligible because of a lacunar syndrome were included only > 6 months after the event to avoid acute effects on the outcomes.
To be able to detect incident dementia and parkinsonism we applied the following exclusion criteria: (a) presence of dementia [25 ] and (b) parkinson(-ism)[26 (link),27 (link)]. In addition patients with (c)intracranial hemorrhage; (d) life expectancy of less than six months; (e) intracranial space occupying lesion; (f) (psychiatric) disease interfering with cognitive testing or follow-up; (g) recent or current use of acetylcholine-esterase inhibitors, neuroleptic agents, L-dopa or dopa-a(nta)gonists; (h) non-SVD related WML (e.g. multiple sclerosis); (i) prominent visual or hearing impairment; (j) language barrier; (k) MRI contraindications or known claustrophobia were excluded.
All participants signed an informed consent form. The Medical Review Ethics Committee region Arnhem-Nijmegen approved the study.
Full text: Click here
Publication 2011
Acetylcholinesterase Inhibitors Antipsychotic Agents Brain Cerebrovascular Accident Claustrophobia Cognition Dementia Dopa Genetic Heterogeneity Hearing Impairment Infarction, Lacunar Intracranial Hemorrhage Levodopa Mental Disorders Multiple Sclerosis Neurobehavioral Manifestations Parkinsonian Disorders Patients Stroke, Lacunar Transient Ischemic Attack

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Alzheimer's Disease Clinical Reasoning Cognition Dementia, Vascular Diagnosis Disorders, Cognitive Executive Function Lewy Body Disease Memory Mental Orientation Mini Mental State Examination Neurobehavioral Manifestations Neurologists Nurses Presenile Dementia Tests, Diagnostic Tic Disorder

Most recents protocols related to «Neurobehavioral Manifestations»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Cognitive Impairments, Mild Hypersensitivity Mini Mental State Examination Neurobehavioral Manifestations Step Test
In this study, the beck anxiety inventory (BAI) was used to test the anxiety level of participants during L2-L1 (English-Chinese, E-C) or L1-L2 (Chinese-English, C-E) translation. Beck anxiety inventory was created by Aaron T. Beck et al., and it comprises a self-report inventory consisting of 21 multiple-choice items describing emotional, physiological, and cognitive symptoms of anxiety.
Full text: Click here
Publication 2023
Anxiety Chinese Emotions Neurobehavioral Manifestations physiology
Chi-square for categorical variables and Mann–Whitney U test for continuous variables due to non-normality were used to compare the baseline characteristics between patients with RLS and RLS-free controls. Cox proportional hazards regression models were applied to explore the association between RLS and the risk of dementia after adjusting for age, sex, income, residence, CCI, and history of other comorbidities. Among the Cox regression models, we used the Fine–Gray subdistribution hazard model with mortality as a competing risk given the old age of the study population. The proportional hazard assumption was satisfied in our Cox model (Schoenfeld individual test p-value > 0.05).
Sensitivity analyses were performed using four different models. In model 1, dementia was defined as the prescription of anti-dementia medications (donepezil, rivastigmine, galantamine, and memantine) at least twice and a diagnosis of the ICD-code of dementia. Although these medications were approved for only AD (rivastigmine additionally for Parkinson’s disease dementia), they can be used for cognitive symptoms in other types of dementia based on recommendations from multiple guidelines [31 (link)–33 (link)]. The previous study revealed that the definition of all-cause dementia by ICD-10 code plus anti-dementia medications had a positive predictive value of 94.7% when reviewing the medical records of 972 patients in two hospitals [34 (link)]. In model 2, medication history was added to the ICD code to define RLS. Patients with RLS ICD-code (G25.8) who had taken dopamine agonists (ropinirole or pramipexole) twice or more were regarded as patients with RLS (n = 1458). In this sensitivity model, we excluded patients with Parkinson’s disease because they could also take dopamine agonists. In model 3, patients taking antipsychotic agents were excluded because the antidopaminergic property of antipsychotic agents could lead to a misdiagnosis of RLS (n = 2482). The following antipsychotic agents approved in South Korea were used in this study: haloperidol, sulpiride, chlorpromazine, perphenazine, pimozide, risperidone, olanzapine, quetiapine, paliperidone, amisulpride, aripiprazole, ziprasidone, clozapine, blonanserin, and zotepine. In model 4, patients with RLS only diagnosed by psychiatrists or neurologists were included (n = 1154) to preclude the possible misdiagnosis by non-expert physicians.
To evaluate the effect of dopamine agonists (pramipexole and ropinirole) on the development of dementia, the risk of dementia was compared after dividing RLS patients by dopamine agonist use. Patients with RLS who were prescribed pramipexole or ropinirole at least once were considered dopamine agonist users. All missing data were addressed using listwise deletion. Data processing and statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Statistical significance was set at a two-tailed p-value of < 0.05.
Full text: Click here
Publication 2023
Age Groups agonists Amisulpride Antipsychotic Agents Aripiprazole blonanserin Chlorpromazine Clozapine Deletion Mutation Donepezil Dopamine Agonists Dopamine Effect Galantamine Haloperidol Hypersensitivity Memantine Neurobehavioral Manifestations Neurologists Olanzapine Paliperidone Parkinson Disease Patients Perphenazine Pharmaceutical Preparations Physicians Pimozide Pramipexole Prescription Drugs Presenile Dementia Psychiatrist Quetiapine Risperidone Rivastigmine ropinirole Sulpiride ziprasidone zotepine
“Darryl” is a cartoon-based assessment tool designed to measure symptoms of possible PTSD according to DSM-IV among school-aged children (19 (link)). The test consists of cartoon pictures illustrating the boy Darryl (in Danish “Thomas”) and is designed to illustrate the boy in different situations where emotional, behavioral, or cognitive symptoms of PTSD occur. Each cartoon depicts a different PTSD symptom, and an interviewer reads aloud the corresponding short script describing the content of the cartoon. The child is asked to respond to the script using one of the three response choices “never”, “some of the time” or “a lot of the time” to describe to what extent the child feels like Darryl. The responses are assigned a score of 0, 1, or 2, respectively (8 (link)). The tests used in this study are the versions designed to reflect one of the two traumas: sexual abuse or physical abuse. The Danish version of the tests consist of 19 items which measure symptoms of possible PTSD which gives a possible range of scores between 0-38. Seven items cover symptoms of re-experiencing, seven items cover symptoms of avoidance, and five items cover symptoms of hyperarousal (22 (link)). Two additional items concern somatic symptoms (headache and stomachache) that are common trauma symptoms in children. Following the DSM-IV (16 ), diagnostic criteria for PTSD were met if participants endorsed at least one symptom of re-experiencing, at least three symptoms of avoidance and at least two symptoms of hyperarousal. The symptom criteria were met if the response was “Some of the time” or “A lot of the time”.
Publication 2023
6-pyruvoyl-tetrahydropterin synthase deficiency Abuse, Physical Child Diagnosis Emotions Feelings Headache Interviewers Medically Unexplained Symptoms Neurobehavioral Manifestations Sexual Abuse Wounds and Injuries
Because cognitive symptoms are hallmark symptoms of septic shock, it will in most cases be impossible to obtain informed consent at the time of presentation.17 (link) The trial will therefore use a deferred consent process. A member of the local research team will approach the legal representative or a personal consultee (relative or close friend) as soon as practically possible to inform about the trial and seek their opinion about the participation of the patient in the trial. Surviving participants will be provided with written and oral information for an informed decision about participation in the trial and asked for written consent as soon as they can make an informed decision. The consent form must be signed by the participant according to Swedish legislation.
A participant is free to withdraw his/her consent from the trial at any time. The participant making the withdrawal will be asked for permission to use data obtained prior to withdrawal and to obtain data for the primary outcome. If permission is obtained, the participant will be included in the final analyses. If the patient declines, all data from that patient will be destroyed.
Publication 2023
Friend Neurobehavioral Manifestations Patient Participation Patients Septic Shock Volition

Top products related to «Neurobehavioral Manifestations»

Sourced in United States, United Kingdom, Japan, Austria, Germany, Denmark, Czechia, Belgium, Sweden, New Zealand, Spain
SPSS version 25 is a statistical software package developed by IBM. It is designed to analyze and manage data, providing users with a wide range of statistical analysis tools and techniques. The software is widely used in various fields, including academia, research, and business, for data processing, analysis, and reporting purposes.
Sourced in United States, Japan, United Kingdom, Germany, Hong Kong, Belgium, Austria
SPSS Statistics version 24 is a statistical software package developed by IBM. It is designed to analyze and manage data, providing users with tools for data manipulation, statistical modeling, and reporting. The core function of SPSS Statistics version 24 is to enable users to perform a wide range of statistical analyses, including descriptive statistics, regression analysis, and hypothesis testing.
Sourced in United States, Japan, United Kingdom, Germany, China, Austria, Ireland, Canada, France, Spain, Switzerland
SPSS Statistics 20 is a software package for statistical analysis. It provides a comprehensive set of tools for data management, analysis, and reporting. The software is designed to handle a wide range of data types and supports a variety of statistical techniques, including regression analysis, hypothesis testing, and descriptive statistics.
Sourced in United States
SAS version 9.4 is a software package that provides tools for data management, analysis, and reporting. It enables users to access, manipulate, and analyze data from various sources. The software includes features for statistical analysis, predictive modeling, and visual data exploration.
Sourced in Germany, Switzerland, United Kingdom, Japan, France, Sweden
The Cobas analyzer is a laboratory instrument manufactured by Roche. It is designed for the automated analysis of various clinical chemistry and immunoassay parameters. The Cobas analyzer provides accurate and reliable results, enabling healthcare professionals to make informed decisions in patient care.
Sourced in United States, United Kingdom, Denmark
Stata V.12 is a software package designed for statistical analysis, data management, and graphics. It provides a comprehensive set of tools for researchers, analysts, and professionals in various fields. The core function of Stata V.12 is to facilitate the analysis of data, including the ability to perform a wide range of statistical tests, create graphs and visualizations, and manage complex datasets.
Sourced in United States
AmpliTaq Gold® 360 PCR Master Mix is a ready-to-use solution for performing polymerase chain reaction (PCR) amplification. It contains DNA polymerase, dNTPs, and PCR buffer components optimized for efficient and reliable DNA amplification.
Sourced in United States, United Kingdom, Austria, Japan
SPSS Statistics for Windows, Version 23.0 is a software application for statistical data analysis. It provides a comprehensive set of tools for data management, analysis, and reporting.
Sourced in United States, United Kingdom, Japan, Germany, Austria, Belgium, France, Denmark
SPSS 24.0 is a statistical software package developed by IBM. It provides data management, analysis, and reporting capabilities. The software is designed to handle a wide range of data types and is commonly used for social science research, market research, and business analytics.
Sourced in United States, Japan, Germany, United Kingdom, Belgium, Austria, Spain
SPSS Statistics 24 is a software package used for statistical analysis. It provides a comprehensive set of tools for data management, analysis, and presentation. The software is designed to handle a wide range of data types and offers a user-friendly interface for conducting various statistical procedures.

More about "Neurobehavioral Manifestations"

Neurobehavioral Manifestations is a broad term that encompasses the intricate interplay between the nervous system and human behavior.
This field of study explores a wide range of neurological and psychological expressions, from cognitive and emotional processing to sensory-motor integration.
Understanding Neurobehavioral Manifestations is crucial for advancing research in various disciplines, including neuroscience, psychology, and medicine.
One of the key aspects of Neurobehavioral Manifestations is the influence of the nervous system on an individual's behavior, cognition, and emotional experiences.
This can include conditions such as autism spectrum disorder, Alzheimer's disease, Parkinson's disease, and traumatic brain injury, among others.
Researchers utilize a variety of tools and techniques, such as SPSS version 25, SPSS Statistics version 24, SPSS Statistics 20, SAS version 9.4, Cobas analyzer, Stata V.12, and AmpliTaq Gold® 360 PCR Master Mix, to investigate the underlying mechanisms and develop effective interventions.
The field of Neurobehavioral Manifestations is constantly evolving, with new discoveries and insights being made through cutting-edge research.
Researchers leverge SPSS Statistics for Windows, Version 23.0, and SPSS 24.0 to analyze data and uncover patterns that can lead to a deeper understanding of the complex relationship between the nervous system and behavior.
By exploring this dynamic field, researchers and clinicians can optimize their workflows and drive breakthroughs in the understanding and treatment of a wide range of neurological and psychological conditions.
Overall, Neurobehavioral Manifestations is a fasinating and rapidly advancing field of study that holds the potential to unlock new insights and improve the lives of individuals affected by neurological and behavioral disorders.
PubCompare.ai's innovative solutions can assist researchers in navigating this complex landscape and identifying the optimal protocols and products for their investigations.